Electrophysiological characterisation of Cellular Dynamics International ventricular iCell2 iPSC-derived cardiomyocytes

Poster Description

To provide a more thorough and predictive cardiac safety profile of new chemical entities, the FDA is introducing the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative. To allow the successful integration of human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CM) as a translational model of human cardiac tissue their physiology needs to be fully characterised.

Here we highlight the work performed at Metrion Biosciences in collaboration with Cellular Dynamics International (CDI) to assess the utility of CDI iCell2 ventricular iPSC-CM for cardiotoxicity screening.

Download
Recommended Publications
Latest Publications
A High-throughput Drug Repurposing Screen of the Potassium Channel, KV3.1, with V434L Mutation (poster)

Manual patch-clamp technique was used to evaluate channel pharmacology using cells transiently transfected with wild-type and V434L mutant channel.

Assessing the variability of hERG data generated using a mock action potential waveform and automated patch clamp platforms

The HESI Cardiac Safety Committee present results from an international ion channel research study that assessed the variability of hERG data generated using automated patch clamp platforms (QPatch 48, Qube 384 and the SyncroPatch 384i) across four different labs.

View All
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram